Robeco Institutional Asset Management B.V. Bei Gene, Ltd. Transaction History

Robeco Institutional Asset Management B.V.

$49.7 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$158.67 - $201.58 $105,991 - $134,655	668 New	668 $120,000
Q4 2023 Feb 08, 2024	SELL	$158.67 - $201.58 $940,595 - $1.19 Million	-5,928 Closed	0 $668,000
Q3 2023 Oct 23, 2023	SELL	$179.87 - $225.13 $2.18 Million - $2.73 Million	-12,118 Reduced 67.15%	5,928 $1.07 Million
Q1 2023 May 03, 2023	BUY	$215.53 - $274.5 $948,763 - $1.21 Million	4,402 Added 32.26%	18,046 $3.89 Million
Q4 2022 Feb 06, 2023	BUY	$125.51 - $229.3 $1.71 Million - $3.13 Million	13,644 New	13,644 $3 Million
Q4 2018 Feb 08, 2019	SELL	$107.01 - $175.15 $1.32 Million - $2.15 Million	-12,302 Closed	0 $0
Q3 2018 Oct 31, 2018	BUY	$152.62 - $189.66 $1.88 Million - $2.33 Million	12,302 New	12,302 $2.12 Million

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

Baker Bros. Advisors LP New York, NY

10.6M
Shares

$2.03 Billion
25.41% of portfolio
Capital International Investors Los Angeles, CA

6.43M
Shares

$1.24 Billion
0.29% of portfolio
Hhlr Advisors, Ltd. Grand Cayman, E9

5.18M
Shares

$995 Million
26.65% of portfolio
Primecap Management CO Pasadena, CA

4.97M
Shares

$956 Million
0.84% of portfolio
Baillie Gifford & CO

3.71M
Shares

$712 Million
0.64% of portfolio

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Robeco Institutional Asset Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Robeco Institutional Asset Management B.V. with notifications on news.

Account